Equities research analysts forecast that Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will report earnings of ($0.64) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Arena Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.59) and the lowest estimate coming in at ($0.71). Arena Pharmaceuticals posted earnings of $1.60 per share during the same quarter last year, which suggests a negative year over year growth rate of 140%. The company is expected to report its next quarterly earnings results on Tuesday, March 13th.

Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Arena Pharmaceuticals.

Arena Pharmaceuticals (NASDAQ:ARNA) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.66) by $0.01. Arena Pharmaceuticals had a negative net margin of 36.78% and a negative return on equity of 34.12%. The firm had revenue of $7.95 million during the quarter, compared to the consensus estimate of $5.48 million. During the same quarter in the previous year, the firm posted ($0.05) earnings per share. The company’s revenue was down 58.6% on a year-over-year basis.

Several analysts have recently weighed in on the stock. BidaskClub raised shares of Arena Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Cantor Fitzgerald reaffirmed a “buy” rating and set a $37.00 price target on shares of Arena Pharmaceuticals in a research note on Monday, September 25th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Arena Pharmaceuticals in a research note on Tuesday, August 8th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Arena Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $36.00.

Hedge funds have recently modified their holdings of the stock. Great West Life Assurance Co. Can increased its holdings in Arena Pharmaceuticals by 128.2% during the third quarter. Great West Life Assurance Co. Can now owns 4,390 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 2,466 shares during the period. Bank of America Corp DE increased its holdings in Arena Pharmaceuticals by 102.0% during the first quarter. Bank of America Corp DE now owns 96,379 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 48,667 shares during the period. Strs Ohio purchased a new position in Arena Pharmaceuticals during the second quarter valued at approximately $156,000. Cubist Systematic Strategies LLC purchased a new position in Arena Pharmaceuticals during the third quarter valued at approximately $174,000. Finally, Airain ltd purchased a new position in Arena Pharmaceuticals during the second quarter valued at approximately $178,000. 72.85% of the stock is currently owned by institutional investors.

Shares of Arena Pharmaceuticals (NASDAQ:ARNA) opened at $30.75 on Monday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 4.32 and a current ratio of 4.42. Arena Pharmaceuticals has a 12 month low of $11.30 and a 12 month high of $31.75.

TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Anticipate Arena Pharmaceuticals, Inc. (ARNA) to Post -$0.64 EPS” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/04/zacks-analysts-anticipate-arena-pharmaceuticals-inc-arna-to-post-0-64-eps.html.

Arena Pharmaceuticals Company Profile

Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).

Get a free copy of the Zacks research report on Arena Pharmaceuticals (ARNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arena Pharmaceuticals (NASDAQ:ARNA)

Receive News & Ratings for Arena Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.